Gene: Siglec15
Official Full Name: sialic acid binding Ig-like lectin 15provided by MGI
Gene Summary: Acts upstream of or within regulation of actin cytoskeleton organization; regulation of bone resorption; and regulation of osteoclast development. Located in plasma membrane. Part of protein-containing complex. Is expressed in eye; immune system; reproductive system; and stomach. Orthologous to human SIGLEC15 (sialic acid binding Ig like lectin 15). [provided by Alliance of Genome Resources, Apr 2025]
Catalog Number | Product Name | Species | Gene | Passage ratio | Mycoplasma testing | Price |
---|---|---|---|---|---|---|
KO01158 | Siglec15 knockout cell line (MC38) | Mouse | Siglec15 | 1:2-1:4 | Negative | Online Inquiry |
KO01226 | Siglec15 Knockout cell line(RAW 264.7) | Mouse | Siglec15 | 1:2-1:3 | Negative | Online Inquiry |
Siglec15 Gene Knockout Cell Lines are advanced cell culture models engineered to lack the expression of the Siglec15 (Sialic acid-binding Ig-like lectin 15) gene, a member of the Siglec family which modulates immune responses through interactions with sialylated glycoconjugates. These knockout cell lines provide researchers with a powerful tool to uncover the biological roles of Siglec15 in immunological contexts, particularly in tumor immunity and inflammation regulation.
The primary function of Siglec15 is to inhibit T cell activation and modulate macrophage responses, thereby playing a crucial role in the immune system's balance between activation and tolerance. The knockout of this gene allows researchers to investigate how the absence of Siglec15 affects immune cell dynamics and interactions, particularly its impact on T cell proliferation and function. Utilizing these cell lines can help illuminate the underlying mechanisms of immune evasion by tumors and the potential therapeutic roles of targeting Siglec15.
The scientific importance of Siglec15 Gene Knockout Cell Lines extends to various research settings, including cancer immunotherapy, autoimmune disease studies, and the development of adjuvants. By providing a controlled environment to study the receptor's signaling pathways, these models facilitate the evaluation of novel immunotherapeutic strategies aimed at enhancing anti-tumor immunity or restoring impaired immune responses.
One of the significant advantages of using Siglec15 Gene Knockout Cell Lines over conventional models is their specificity and reliability. Unlike non-targeted approaches that may suffer from off-target effects, these knockout lines ensure a clean slate for investigating the direct role of Siglec15, allowing for more accurate interpretations and reproducible results.
For researchers and clinicians focused on advancing the field of immunology and improving therapeutic outcomes, the value of these specialized cell lines cannot be overstated. They represent a critical resource for elucidating complex immune interactions and paving the way for innovative treatments.
Our company specializes in producing high-quality biological products tailored for rigorous research and clinical applications, ensuring that our offerings meet the highest standards of scientific excellence and reliability.
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.